This paper reports the effect of particle size within a resorbable composite on the in vivo degradation rate and host response. Resorbable composites based on poly(D,L-lactide-co-glycolide) (PLGA) reinforced with tricalcium phosphate (TCP) have shown suitable degradation, biological and mechanical properties for bone repair. Composites with nano-sized TCP particles degrade more homogenously in vitro than equivalent composites with micro-sized particles. In this study, PLGA and PLGA/TCP composites containing micro-or nano-sized a-TCP particles were implanted into an ovine distal femoral condyle defect and harvested at 6, 12, 18 and 24 weeks. An intimate interface was observed between the new bone tissue and degrading implants. Visual scoring of histological images and semi-automated segmentation of X-ray images were used to quantify implant degradation and the growth of new bone tissue in the implant site. Bone growth into the implant site occurred at a similar rate for both composites and the PLGA control. However, the in vivo degradation rate of the nanocomposite was slower than that of the microcomposite and consequently more closely matched the rate of bone growth. For the first 6 weeks, the rate of in vivo degradation matched that of in vitro degradation, but lagged significantly at longer time points. These results point to the potential use of ceramic particle size in controlling composite degradation whilst maintaining good bone formation.
1. Introduction
PLGA/a-TCP composites
Composites based on poly(a-hydroxy) acids and calcium phosphates show promising degradation characteristics and mechanical properties for use as an orthopaedic biomaterial [1] [2] [3] . Poly (lactide-co-glycolide) is widely used in medicine as drug delivery devices, suture anchors, screws and plates [4, 5] . However, when PLGA degrades acidic oligomers build up inside the sample and can be released suddenly, leading to a local reduction in pH. Calcium phosphates have been widely used in orthopaedic repair for over 20 years [6] . Tricalcium phosphate (TCP) forms a direct bond with bone and has been used successfully as a bone replacement material [7, 8] . Adding TCP to PLGA to form a composite reduces the pH drop as TCP particles dissolve and buffer the acidic degradation products [9] . There are several parameters that can be altered in order to tailor the degradation profile of the composite for a specific application. These include the characteristics of the polymer matrix (e.g. crystallinity), the type of calcium phosphate (e.g. a-TCP, b-TCP, hydroxyapatite (HA)), the composite processing method and the weight fraction, size and shape of the calcium phosphate reinforcement.
The effect of ceramic particle size in resorbable composites
As bone itself is a nanostructured composite, polymer matrix composites with a nano-sized reinforcement phase (i.e. with dimensions less than 1000 nm) have been investigated for use in orthopaedic repair [10] [11] [12] [13] .
Mechanical properties
Reducing particle size in polymer based particulate composites generally results in increased mechanical properties such as stiffness and tensile strength [14] . However, due to their increased surface area, nano-sized particles have a tendency to agglomerate during composite preparation. This agglomeration can lead to conflicting results regarding the effect of particle size on composite properties. The incorporation of nano-sized, rather than microsized, HA and TCP particles dispersed in the matrix resulted in higher 4-point bending strength and higher modulus of elasticity in composites made of a polyamide fabric with a polysiloxane matrix [15] . This was attributed to the better dispersion of the nano-particles compared to micro-particles and their closer proximity to the polyamide fibres. Conversely, the 3-point bending strength and modulus of elasticity of poly(L-lactide)/HA and PLGA/HA composites were higher with a HA particle size of 5 lm than with a HA particle size of <200 nm [16] . This was attributed to poor particle distribution in the composites with smaller particles.
Degradation behaviour
The in vitro degradation behaviour of composites with nanosized particles has been shown to be more favourable than those containing micro-sized particles. Freeze dried poly(lactide)/b-TCP composites with nano-sized b-TCP particles were found to have a stronger buffering effect in vitro than composites with microsized b-TCP particles [9] . The in vitro degradation of PLGA/a-TCP nanocomposites was found to be slower and more homogeneous than that of microcomposites with the same ceramic loading [17] . Significant mass loss for nanocomposites occurred after 43 days, compared with 36 days for microcomposites and 21 days for PLGA control samples. The nanocomposites absorbed less water (resulting in less swelling) and the degradation environment was less acidic than with equivalent microcomposites. It is possible that a-TCP may change phase to less soluble phases during the hydrolytic degradation of the polymer degradation although an XRD study of degrading PGA/a-TCP composites failed to find conclusive evidence for this [18] .
Biological response
There is good evidence that adding nano-sized ceramic particles to poly(a-hydroxy) acids improves the biological response of these materials. The addition of nano-sized b-TCP enhanced the osteoconductivity of freeze-dried poly(lactide)/b-TCP composite scaffolds at 8 weeks in vivo although there was no difference in response at 2 and 4 weeks, implying that the difference in response may not have been a function of the initial structure [9] . In vitro cell culture of PLGA/a-TCP composites with human osteoblasts showed improved cell attachment and spreading of osteoblast cells, more rapid cell proliferation and a higher degree of osteoblast differentiation on nanocomposites in comparison with equivalent microcomposites [19] . In an in vivo study in a minipig model micro and nanocomposites of bTCP with a high lactide to glycolide polymer ratio showed greater push-out force than polymer only at 8 weeks however minimal implant degradation was seen at this time point [20] .
The improved mechanical properties, degradation behaviour and cell culture behaviour reported in the literature suggest that nanocomposites have advantages over equivalent microcomposites as orthopaedic implant materials. In this study, PLGA/a-TCP composites were produced with micro-and nano-sized TCP particles in order to investigate the effect of TCP size on the performance of the composite in vivo. The choice of aTCP as a filler phase allowed direct comparison with earlier in vitro studies [17] .
Methods

Material preparation
PLGA with a 50:50 M ratio of D,L-lactide to glycolide was purchased (Lakeshore Biomaterials, Birmingham, Alabama, USA) with a molecular weight of 65 kDa and an inherent viscosity of 0.47 dL/ g. a-TCP was synthesised in-house via an aqueous precipitation reaction between 98% Ca(OH) 2 and 85% ortho-H 3 PO 4 at a molar ratio of 3:2. The dried TCP cake was ground and calcined to obtain the metastable a-TCP phase using the following furnace program: heat at 2.5°C/min to 1400°C, dwell for 4 h at 1400°C and cool at 20°C/min to 20°C. After calcining, a solid lump of a-TCP was obtained which was broken down to a powder using a pestle and mortar. X-ray diffraction was used to identify the phase of the calcined TCP. Semi-quantitative analysis of the spectra using Highscore Plus software (PANalytical, Almelo, Netherlands) showed that the calcined TCP powder consisted of 100% a-TCP. Attenuated total reflectance Fourier transform infrared spectroscopy (ATR-FTIR) also confirmed that the TCP powder was the a-polymorph.
The Ca/P ratio of the calcined TCP powder determined with X-ray fluorescence (XRF) spectroscopy was 1.53 ± 0.005, which is close to the nominal Ca/P ratio of TCP of 1.50. Analytical reagent grade acetone was used as the solvent for preparing the materials at a solvent: polymer ratio of 5:1. Further acetone was added during processing to compensate for solvent evaporation. The microcomposite material was produced by dispersing a-TCP powder in acetone for approximately 10 min using a magnetic stirrer, adding the PLGA pellets and stirring the mixture for a further 30 min. The nanocomposite material was produced by attritor-milling (PE 075/ PR 01, Netzsch-Feinmahltechnik GmbH, Selb, Germany with attritor agitator shaft and 2 mm diameter spherical alumina beads) a-TCP powder in acetone for 2 h, gradually adding the PLGA pellets and milling the mixture for a further 30 min. Both microcomposite and nanocomposite materials contained 30 wt% a-TCP. The polymer material was produced by attritor-milling PLGA in acetone for 30 min without the addition of a-TCP. After mixing in acetone, all materials were dried in air in PTFE containers with a height of approximately 80 mm and a diameter of approximately 60 mm for 2-4 days to evaporate the acetone. This was followed by further drying in a vacuum oven at a temperature of 50°C and a vacuum pressure of 800 mbar for approximately 4 days to remove any residual acetone. The materials were then injection moulded using a micro-injection moulder (DSM Research, Heerlen, Netherlands) to produce cylindrical samples of length 12 mm and diameter 6 mm. Twenty-four samples of each material were prepared for implantation, sufficient for 6 replicates to be harvested at each of 4 time-points. All materials were sterilised by exposure to gamma radiation (25 kGy absorbed dose, Isotron, Swindon, UK) prior to implantation. Before fabrication, the polymer was stored in a desiccator to avoid moisture capture. After fabrication, the sample were dried in a vacuum oven at 50°C at 500 mbar. After removal from the oven samples were stored in a desiccator or in polyethylene containers under inert atmosphere. Although injection moulding and irradiation may affect the molecular weight of the polymer, all formulations were subjected to these processes so the relative MWs are likely to have remained similar. We do not think that the differences in processing required to produce micro-and nano-composites are likely to have resulted in very different molecular weights between the formulations. The number of replicate samples per implant type per time point was determined on the basis that significant differences in bone formation between groups were seen in studies of bone graft substitute materials using a similar implantation model [21] with the same number of replicates per group.
Material characterisation
TCP particle size
Scanning electron microscopy (SEM) was used to characterise the morphology of the composite materials and the dispersion state of the a-TCP particles in the PLGA matrix. For microcomposites, a low-vacuum W-filament SEM (JEOL JSM-5800LV) with an accelerating voltage of 10 kV was used. 15 micrographs of the microcomposite were obtained, from which at least 6000 particle sizes were measured. In order to resolve the features of the nanocomposites, a cold field emission electron gun (cFEG) SEM (Hitachi S-5500) with an accelerating voltage of 2 kV was used. Samples were frozen using liquid nitrogen and SEM specimens were chipped off using a sharp razor blade and hammer.
Back-scattered electron mode was used to differentiate the a-TCP particles (white) from the PLGA matrix (grey). Micrographs were obtained from at least four different regions of each sample. At least 20 micrographs of the nanocomposite were obtained, from which at least 250 particle sizes were measured.
TCP weight fraction
Thermogravimetric analysis (TGA) (Q500 QA Instruments) was used to determine the actual weight% of TCP in the composite samples and to confirm the removal of acetone. Nitrogen and air were used as the balance gas and sample gas, respectively, for the TGA experiments. A pre-weighed amount of material between 5 mg and 15 mg was heated at a rate of 10°C/min from approximately 12°C to 600°C.
Animal model
An ovine model was chosen due to the similarities with humans in weight, bone and joint structure and bone regeneration [21] . A defect size of 12 mm deep and 6 mm in diameter was used to accord with the size of the injection moulded implants. This is sub-critical but was suitable for comparing the response of bone to the different implant materials.
Surgical procedure
All procedures were carried out in accordance with the regulations set out in the Animals (Scientific Procedures) Act 1986 and were approved by the local animal study ethics committee. The animals used were Welsh Mountain ewes aged between 2 and 5 years and weighed 30-50 kg. A total of thirty-six animals had bilateral bone defects produced in the distal femoral condyle as previously described [22, 23] . Anaesthesia was induced with Alfaxolone (Alfaxan Ò ) (3 mg/kg i.v.) and maintained using 2.5% Isoflurane and 1.5% nitrous oxide. Depocillin (50 mg/kg i.m.) and Carprofen (Rimidyl Ò ) (1.5 mg/kg s.c.) were given peri-operatively to produce antibiotic and analgesic cover respectively. The skin over both hind limbs was shaved and scrubbed for sterile surgery. An incision was made over the lateral femoral condyle and the surface of the condyle exposed. The defect was drilled using a 6 mm diameter drill bit with a drill stop collar set at 12 mm. The defect was rinsed with sterile saline and the implant inserted in a 'press fit' manner. Nine animals were randomly assigned to each of four groups for implantation times of 6, 12, 18 and 24 weeks and within each group the polymer only, microcomposite and nanocomposite materials were randomly assigned to each defect site. Subcutaneous tissue and skin were closed routinely and the animals allowed to recover quietly. On recovery the animals were allowed full weight-bearing. Carprofen (1.5 mg/kg) was given eighteen hours after surgery and Depocillin (50 mg/kg) on post-operative days 1 and 2. The fluorochrome labels calcein (15 mg/kg) and alizarin red (40 mg/kg) were given by intravenous injection into the cephalic vein 14 and 7 days respectively prior to sacrifice. At the appropriate time points; weeks 6, 12, 18 and 24, the animals were killed by an overdose of intravenous pentobarbitone. The femoral heads were removed en-bloc and placed in fresh, ice cold 4% w/v paraformaldehyde. After fixation the femoral heads were rinsed in saline and l-CT carried out. The l-CT images were used to orientate the bone for sectioning.
Implant embedding and sectioning
Initial cuts were made around the implant site to remove extraneous bone and the remaining bone containing the implant was dehydrated by sequential transfer through 40%, 70%, 90% and 100% v/v alcohol; each solution being changed twice over a period of twenty-four hours. Following a further change of 100% alcohol, the samples were defatted in acetone and then infiltrated in methylmethacrylate resin over a period of one week, with the resin being changed on one occasion. Fresh resin containing 2.5% v/v dibutylphthalate and 2.5% w/v benzoyl peroxide was added to the specimens and the resin allowed to polymerise in glass jars. Cutting of the resin blocks containing the implants and surrounding bone was carried out using an Accutom 5 rotating saw (Struers) with a diamond impregnated blade. The resin blocks were removed from the jars, cut to a manageable size and cut through the centre of the longitudinal axis of the implant site using the lCT images as a guide. Sections were cut parallel to this central cut for staining and analysis. Sections were ground flat and polished using diamond impregnated pads and diamond paste respectively on a Rotopol 21 polisher (Struers). The sections were glued to Perspex slides (70 Â 40 Â 2 mm) using cyanoacrylate glue.
Staining
Sections were surface-stained with 0.25% w/v toluidine blue (pH 9) at 56°C for 30 min in order to observe the presence of osteoid, and the distribution and organisation of cells within the tissue. The staining also allowed residual composite material to be seen.
Histology and visual scoring
Stained sections were examined using a light microscope (Leitz Dialux 20, Leica, UK). The presence of inflammatory mononuclear cells, osteoclasts and evidence of bone resorption was recorded.
Representative images were captured using a QImaging camera and Surveyor software (Objective Imaging, UK).
The percentages of bone and implant in the implant site were estimated by examining the stained sections under the microscope using a low power (Â1) objective providing a score for each section. The area of trabecular bone tissue was scored between 0 and 50% of the area assessed in increments of 10% and the area of residual implant was scored from 100% to 0% of the area assessed again with increments of 10%. Confirmation of the identity of the bone or implant material during scoring was done using a Â10 objective as required. Scoring was done by one observer who was not aware of the time of harvest or the implant material in each section.
2.8. X-ray scoring 2.8.1. X-ray image acquisition and preparation X-ray images of 72 cross-sections were taken using a Kubtec Xpert 80 and Digicom 4.0 software, with an X-ray source voltage of 30 kV and current of 800 lA. Samples were placed in the same position in the X-ray chamber to minimise any variations in image intensity due to the X-ray source. X-ray images were analysed using Fiji [24] , an image processing package based on ImageJ. The images were scaled and a rectangle of size 5.5 mm Â 11.5 mm positioned over each implant site and cropped. The brightness and contrast of the images were equalised using the automatic settings in Fiji.
X-ray image segmentation
The implant sites in this study were categorised into four distinct groups: those which contained no bone or implant (not shown), those which contained bone only (see Fig. 1a ), those which contained implant only (see Fig. 1b ) and those which contained both bone and implant (see Fig. 1c) . A trainable image segmentation plugin [25] was used to segment the images and quantify the areas of bone and implant present. These values were expressed as a percentage of the area assessed. The plugin was trained for one image in each group and then applied to the remainder of the images in the group. This method ensures that the regions are being segmented correctly, as the user has trained the program to identify the different pixel intensities, but the segmentation process is automated which removes any bias from the user. The user was not aware of the time of harvest or the implant material for any of the images.
Statistics
%Bone and %Implant data from visual scoring and X-ray segmentation were analysed using SPSS Statistics 20 (IBM, USA). Non-parametric statistical tests were used, which make no assumptions about the probability distributions of the data. The Kruskal-Wallis test was used to compare the data at each timepoint and when significance was seen (p < 0.05), pairwise comparisons were carried out using the Mann-Whitney U test. Fig. 2 shows example micrographs for the micro-and nanocomposite materials. Fig. 3 shows particle number histograms for the microcomposite and nanocomposite materials.
Results
Material characterisation
TGA showed that the actual weight% of TCP in both microcomposites and nanocomposites was relatively close to 30 wt% (see Table 1 ).
Bone ingrowth and implant degradation
Two different independent methods were used to analyse bone ingrowth and implant degradation: visual scoring from histological images and segmentation of X-ray images. The data from these methods are very similar, which confirms that the data is representative of the material differences.
Figs. 4 and 5 show %Bone and %Implant data respectively, as determined by visual scoring and X-ray segmentation as a function of degradation time. Due to the nature of biological data, there was sometimes a large spread in the values for each time point. Both methods show similar trends for both bone ingrowth and implant degradation.
Statistics
Using non-parametric statistics (no assumptions about normality and variance) to analyse the visual scoring and X-ray segmentation %Bone data the Kruskal-Wallis test (more than 2 groups, in this case 3) showed there was no difference between the amount of bone as a function of implant type at any time point. The X-ray segmentation %Implant data showed there were significant differences between the amount of remaining implant as a function of implant type at 12, 18 and 24 weeks (p < 0.05 in each case). This is primarily due to the absence of residual implant in the polymer samples. The Mann Whitney U test showed a significant difference between the micro-and nanocomposite (0.026) at 12 weeks but not at 24 weeks (0.18). Although the visual scoring showed a very similar time course for bone formation and loss of implant within the implant site to that seen with X-ray segmentation (see Fig. 5 ), comparison of the scores for the 3 materials at each time point did not reach statistical significance. Fig. 6 shows mosaic histological images of cross-sections of the implant sites for a 6 week polymer, 24 week microcomposite and 24 week nanocomposite sample.
Histology
The majority of implant sites were surrounded by trabecular bone, however some were inserted adjacent to the marrow cavity (see Fig. 6a ). There was very little implant left in any of the polymer implant sites, even at the earliest time-point. Fig. 6a shows an implant site for a 6 week polymer sample which is full of granulation tissue and contains a small amount of polymer (<10%) but no new bone tissue. Compared with the polymer implants, microcomposite and nanocomposite implants were slower to degrade. There was generally more residual nanocomposite implant than microcomposite implant for a given timepoint. Fig. 6b and c show a microcomposite and nanocomposite implant site respectively at 24 weeks degradation. There is more residual implant (stained grey/black) in the nanocomposite sample than the microcomposite sample and both implant sites contain new bone tissue surrounded by granulation tissue. Fig. 7a -c shows magnified areas of sections taken with an optical microscope. No large aggregates of mononuclear cells indicating a gross inflammatory or immunological response were observed in any samples. An intimate interface was seen between new bone tissue and degrading microcomposite and nanocomposite implants (see Fig. 7a ), which was not seen in polymer samples. Large multinucleated cells resorbing bone were observed in all materials at the earliest time-point only (see Fig. 7b ). Multi-nucleate cells were also seen resorbing the composite implant materials. Fig. 7c shows a large multi-nucleated cell resorbing a nanocomposite implant. Fig. 7d shows continuing bone formation in a nanocomposite implant site between 22 and 23 weeks, evidenced by the separation of the two fluorochrome labels.
Discussion
Effect of TCP on PLGA degradation
In this work the addition of a-TCP to PLGA slowed the in vivo degradation significantly (see Fig. 5b ). The results of this study were compared with previous work on equivalent materials in order to determine whether rates of degradation in vitro corresponded to those seen in vivo. Fig. 8 shows residual %Implant data from visual scoring and X-ray scoring from this in vivo study and % Implant remaining data from an in vitro study with equivalent materials [17] . In the experiment reported all samples were degraded in 0.01 M PBS solution at 37 C without agitation. A sample mass to PBS volume ratio of 6 mg/mL was used for both composite and PLGA samples. PBS solutions were unchanged during the whole period of degradation. pH changes in the degradation experiment are reported in [17] . Note: the in vitro experiment is shorter than the in vivo experiment.
The graphs in Fig. 8 show that at around 6 weeks (42 days) of degradation, the amount of implant remaining was similar for in vitro and in vivo data (around 10% for PLGA, 65% for microcomposite and around 80% for nanocomposite). However, the degradation of composites proceeds more rapidly in vitro after 6 weeks compared to in vivo. One reason for this could be the differing pH environments between the studies. In vitro, the buffering effect of PBS (phosphate-buffered saline) is overwhelmed after about 45 days and the pH of the degradation media drops to below 4 by 85 days [17] . Both the rate of hydrolysis of PLGA and the solubility of TCP increase at lower pH, increasing the rate of sample degradation. In contrast, in vivo the acidic degradation byproducts can be removed from the vicinity of the implant site and so acidic catalysis of implant degradation is reduced. Enzymes (present in vivo but not in vitro) can accelerate the degradation of resorbable polymers, however the published data on the role of enzymes on PLGA degradation is unclear [26] [27] [28] . The fact that physiological pH is likely to be maintained in the in vivo study, but not the in vitro study, is likely to be a significant factor in the difference in degradation rates between the studies.
Effect of TCP particle size
The results of this study show that modifying the particle size alters the in vivo degradation properties of PLGA/TCP composites (p = 0.026 at 12 weeks between microcomposite and nanocomposite). Both visual and X-ray scoring show that the nanocomposite degraded at a slower rate than the microcomposite. This effect was also observed previously in vitro [17] , where the difference was attributed to more effective buffering from the nano-sized TCP particles. An intimate association was seen between the tissue and both the microcomposite and the nanocomposite implants reflecting the biocompatible nature of these materials in osseous tissue.
Clinical relevance
Nanocomposite implants degraded more slowly than microcomposite implants (see Fig. 5 ). Cellular breakdown of the implant was observed in nanocomposite implants (see Fig. 7 ) and fluorescent labelling indicated that bone forming cells were still active between 22 and 23 weeks (Fig. 7d) . Therefore the nanocomposite implant shows potential for use in humans, where a relatively slow degradation rate with intimate bone ingrowth and good biological activity in the implant site is desirable. If implant degradation is too fast compared to the rate of bone growth then a hole could be left in the bone, as seen with the pure PLGA implant (see Fig. 6a ) which would not subsequently fill with bone in a critical size defect. The composite degradation rate was affected by particle size, indicating that this variable could be used to produce implants with tailored degradation profiles. Bone resorption (osteoclast activity) is a concern; however, it was only seen at the early time-point (6 weeks) and was seen in around all materials.
Conclusions
A semi-automated segmentation method was used to identify bone and implant in X-rays of implant sites. The method gave very similar results to those obtained by histological examination, so it could be used as a quick and easy method of quantifying degradation in the laboratory. However it is limited to radio-opaque materials and tissues. The implant degradation seen in vivo correlates well with data from in vitro studies of similar materials for the first 6 weeks of degradation. After 6 weeks the in vivo and in vitro degradation rates differ (probably due to differing local pH environments) but the ranking of the rates is consistent. Bone growth into the implant site occurred at a similar rate for polymer, microcomposite and nanocomposite implants in vivo over 24 weeks. However, the nanocomposite implants degraded more slowly than microcomposite implants. The nanocomposite may therefore be more appropriate for orthopaedic implants in human patients where the rate of bone ingrowth (30% new bone coverage at 24 weeks) is more closely matched by the slower degradation of the nanocomposite (60-75% lost at 24 weeks) than the microcomposite (90-95% lost at 24 weeks). An intimate interface was seen between the new bone tissue and the degrading implants for both the microcomposite and nanocomposite materials. Osteoclast activity resorbing bone was observed around all implant materials, but only at the earliest time-point (6 weeks). Multinucleate cells were seen at later time points but were confined to resorbing the implant material.
